FDA Grants Two Breakthrough Therapy Designations to AbbVie's Temab-A
ABBV sits 41% above its 52-week low of $190.75.
Summary
AbbVie's telisotuzumab adizutecan (Temab-A) received two Breakthrough Therapy Designations from the FDA for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC). This is a significant regulatory milestone that could accelerate development and review timelines for the drug in these indications. The designations follow a series of positive pipeline updates for AbbVie, including the recent FDA approval of JUVMO for Parkinson's disease. While the designations do not guarantee approval, they signal FDA recognition of the drug's potential in areas of high unmet need. The news adds to AbbVie's oncology momentum and may support the stock's current near-52-week-high valuation.
At the time of this announcement, ABBV was trading at $268.31 on NYSE in the Life Sciences sector, with a market capitalization of approximately $471.3B. The 52-week trading range was $190.75 to $269.39. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.